{"analyses":[{"groupDescription":"Stratified Analysis; Stratification factors: Prior exposure to proteasome inhibitors (naïve versus sensitive), and number of prior lines of therapy (1 versus 2 or 3)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.1","upperLimit":"67.2","value":"60.3"},{"groupId":"OG001","lowerLimit":"28.5","upperLimit":"48.6","value":"38.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \\[CR\\], or Stringent complete response \\[sCR\\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group","title":"Very Good Partial Response (VGPR) or Better Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}